文献速递胸部神经MR

MRI影像组学预测接受表皮生长因子受体酪氨酸激酶抑制剂治疗的非小细胞肺癌脑转移患者颅内进展

MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.
PubMed 文献 · Clin Radiol · 2024-01-23

研究纳入70例接受一线EGFR-TKI治疗的EGFR突变非小细胞肺癌脑转移患者(共212个脑转移灶),从治疗前增强T1加权图像提取影像组学特征并计算每位患者的平均rad-score。33例(47.1%)出现颅内进展,EGFR-19del突变(OR 0.19)、第三代TKI治疗(OR 0.33)和平均rad-score(OR 5.71)为独立预测因素,联合模型在训练集和验证集的AUC分别为0.86和0.84。

要点

  • 平均rad-score每升高一个单位,颅内进展风险增加(OR 5.71,95%CI 1.65-19.68)。
  • EGFR-19del突变和第三代TKI治疗与较低的颅内进展风险相关(OR分别为0.19和0.33)。
  • 联合EGFR-19del、第三代TKI和平均rad-score的模型预测颅内进展的AUC在训练集为0.86、验证集为0.84。

核心结论

  • 整合EGFR-19del突变、第三代TKI治疗和平均rad-score的模型对EGFR-TKI治疗后非小细胞肺癌脑转移患者的颅内进展具有良好预测价值。

研究设计与样本

  • 研究纳入70例接受一线EGFR-TKI治疗的EGFR突变非小细胞肺癌脑转移患者(共212个脑转移灶),从治疗前增强T1加权图像提取影像组学特征并建立每个脑转移灶的rad-score及每位患者的平均rad-score,采用单因素和多因素logistic回归筛选预测因素并构建预测模型和列线图。

诊断标准与关键数值

  • 基于EGFR-19del突变、第三代TKI治疗和平均rad-score三个预测因素的模型在训练集和验证集的AUC分别为0.64、0.64、0.74、0.86和0.64、0.64、0.75、0.84,联合模型预测颅内进展性能最优。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To identify clinical and magnetic resonance imaging (MRI) radiomics predictors specialised for intracranial progression (IP) after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in non-small-cell lung cancer (NSCLC) patients with brain metastases (BMs).

MATERIALS AND METHODS: Seventy EGFR-mutated NSCLC patients with a total of 212 BMs who received first-line EGFR-TKI therapy were enrolled. Radiomics features were extracted from the BM regions on the pretreatment contrast-enhanced T1-weighted images, and the radiomics score (rad-score) of each BM was established based on the selected features. Furthermore, the mean rad-score derived from the average rad-score of all included BMs in each patient was calculated. Univariate and multivariate logistic regression analyses were performed to identify potential predictors of IP. Prediction models based on different predictors and their combinations were constructed, and nomogram based on the optimal prediction model was evaluated.

RESULTS: Thirty-three (47.1 %) patients developed IP, and the remaining 37 (52.9 %) patients were IP-free. EGFR-19del mutation (OR 0.19, 95 % CI 0.05-0.69), third-generation TKI treatment (OR 0.33, 95 % CI 0.16-0.67) and mean rad-score (OR 5.71, 95 % CI 1.65-19.68) were found to be independent predictive factors. Models based on these three predictors alone and in combination (combined model) achieved AUCs of 0.64, 0.64, 0.74, and 0.86 and 0.64, 0.64, 0.75, and 0.84 in the training and validation sets, respectively, and the combined model demonstrated optimal performance for predicting IP.

CONCLUSIONS: The model integrating EGFR-19del mutation, third-generation TKI treatment and mean rad-score had good predictive value for IP after EGFR-TKI treatment in NSCLC patients with BM.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Qu J, Zhang T, Zhang X, et al. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Radiol. 2024. PMID: 38310058. doi:10.1016/j.crad.2024.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。